Stifel 2026 Healthcare Conference - KESTRA MEDICAL TECHNOLOGIES LTD

Explicit Guidance:

• Fiscal 2027 Revenue Growth: Management expects full-year results to be delivered with high confidence based on run-rate visibility; second-half 2027 revenue is projected to represent 55% of the full-year total (compared to 45% in the first half) as new sales territories ramp.
• Gross Margin Trajectory: Targeted long-term gross margin of 70% to mid-70%, rising from current "low 80s" toward an "entitlement" of low 90s as in-network coverage expands; anticipated expansion rate of a few percentage points per year.
• Operating Expense (OpEx) vs. Revenue: Pathway to profitability supported by projected OpEx growth of approximately 20%, coupled with top-tier revenue growth and gross margins in the 70–75% range.
• Headcount/Territory Expansion: Addition of 30–40 new sales territories in the current year following a 50-territory expansion in the prior year; scaling of clinical specialists and support staff to match.

Business-Segment Outlook:

• WCD Market Growth: The wearable cardioverter defibrillator (WCD) market grew 14% (dollar basis) in the last fiscal year; projected to be a sustained long-term growth story as only 1 in 7 of the 850,000 eligible patients annually are currently prescribed the device.
• Pipeline Innovation (Non-Ischemic Data): Completion of post-discharge survival data analysis from the ACE-PAS registry expected within 12–18 months to support guideline upgrades and payer coverage for non-ischemic cardiomyopathy patients.
• New Product Capabilities (Late-Stage): A late-stage project to extend issuer performance (beyond current WCD capabilities) expected to be ready for regulatory submission before the end of the calendar year; aims to differentiate the product and potentially command higher rental rates.
• Blood Pressure Monitoring: BioBeat co-development project currently in R&D; regulatory and commercial launch expected in the short term (not a multi-year project) to add monitoring capabilities to the Assure platform.
• Customer Experience (CX): Establishment of a Senior VP of Customer Experience role to ensure 24–48 hour fulfillment of prescriptions, focusing on sales, service, and patient care efficiency.
• Platform Evolution (Assure): Evolution of the Assure platform over 3–5 years to mimic paramedic capabilities (monitoring and therapy) in a wearable form factor, expanding into diagnostic benefits and potentially new patient populations.

Market and Competitive Outlook:

• Share Capture Strategy: Accelerated share capture anticipated via clinical differentiation and new product capabilities; ability to transition patients from out-of-network to in-network reimbursement to improve margins and utilization.
• Category Amplification: Market growth driven by combined clinical data from Kestra and competitors (40,000+ patients) validating higher risk in non-ischemic populations, leading to broader physician adoption.
• Payer Expansion: Recent success in expanding national payer coverage to include non-ischemic patients (an outlier previously); continued focus on converting the remaining ~3,000 US payers.
• Guideline Influence: Management anticipates that long-term survival data (post-discharge to 6 months) will facilitate an upgrade in clinical guidelines for WCD usage; no new randomized controlled trials are expected to be required.

Macro / Industry Outlook:

• Operational Efficiency: Heavy reliance on AI automation for revenue cycle management (prior authorizations, medical record reviews) and patient logistics (device return/refurbishment) to bend cost curves and avoid proportional headcount increases during scaling.
• Regulatory Environment: Anticipated short-term regulatory milestones for new features (blood pressure, extended performance) followed by long-term guideline evolution based on real-world evidence rather than new trials.
• Supply Chain: Critical focus on aligning capex and inventory levels with the ramping sales force to maintain service levels and prevent supply-demand bottlenecks.

Strategic Initiatives:

• AI Integration: Deployment of AI agents for outbound patient contact, inbound customer care (bot resolution), prior authorization automation, and sales territory/account planning to improve productivity and share retention.
• Medical Education: Significant investment in app education and regional medical programs to influence the prescription process among clinicians.
• Sales Force Scaling: Stepwise addition of 30–40 territories this year, supported by clinical specialists, to capture market share from the existing patient pool.

Risks and Headwinds to Outlook:

• Payer Mix Conversion: The timeline to convert the long tail of 3,000+ payers to in-network status is described as a "journey," potentially impacting the pace of gross margin expansion.
• Execution Scaling: Risk of operational misalignment if sales ramp, supply chain, and customer service do not scale at the same rate; requires precise sync of demand and supply.
• Guideline Uncertainty: The timing of guideline updates remains unpredictable as the process is flexible by design; reliance on real-world data interpretation introduces timing variability.

Management Tone on the Future:

• Confidence Level: High confidence in execution and guidance, described as a "fair way down the middle" with a "conservative" framework backed by clear line-of-sight to run rates.
• Strategic Focus: CEO's attention is shifting from immediate execution to long-term strategy (4–5 year horizon) due to high confidence in the team's ability to handle near-term operations.
• Narrative Consistency: Reiteration of the "execution story" and commitment to delivering on previously stated milestones (e.g., 12 quarters of gross margin expansion, AI implementation).

Miscellaneous:

• Clinical Data Milestone: Post-approval study data now encompasses 21,000 patients (Kestra) vs. 19,000 (competitor), totaling 40,000 patients validating the market's need for WCDs in non-ischemic populations.
• Revenue Model: Continued reliance on a rental model where unit economics drive margin expansion through volume leverage and in-network rate optimization.